You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 127 No. 1, January 2009 TABLE OF CONTENTS
  Archives
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Related letters
 •Similar articles in this journal
 Topic Collections
 •Ocular/ Adnexal Tumors
 •Diagnosis
 •Prognosis/ Outcomes
 •Genetics
 •Genetic Counseling/ Testing/ Therapy
 •Genetics, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

COMMENTS AND OPINIONS
Genomic Typing of Uveal Melanoma—Reply

Jerry A. Shields, MD; Carol L. Shields, MD; Miguel Materin, MD; Takami Sato, MD; Arupa Ganguly, PhD

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In reply

We appreciate the comments of Damato and Coupland regarding the controversial issues related to cytogenetics of uveal melanoma. It appears that they basically agree with our views on this subject, but have concerns regarding the comments of Robertson and Tsai and of O’Brien.1-3

A couple of points require further comment.

We continue to advocate medical follow-up for patients with uveal melanoma with both disomy 3 and monosomy 3 abnormality. Our evaluations of those patients currently include physical examination and laboratory testing for lactate dehydrogenase and alkaline phosphatase levels twice per year, and a chest x-ray and abdominal imaging with ultrasound, computed tomography, or magnetic resonance imaging once per year. This evaluation is offered because some patients with disomy 3 melanoma will develop metastasis. Furthermore, most patients with cancer desire systemic monitoring . . . [Full Text of this Article]


AUTHOR INFORMATION


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

Anterior Segment Optical Coherence Tomography as a Diagnostic Tool for Cyclodialysis Clefts
Aránzazu Mateo-Montoya and Sylvain Dreifuss
Arch Ophthalmol. 2009;127(1):109-110.
EXTRACT | FULL TEXT  

Role of Cytogenetics in Management of Uveal Melanoma
Jerry A. Shields, Carol L. Shields, Miguel Materin, Takami Sato, and Arupa Ganguly
Arch Ophthalmol. 2008;126(3):416-419.
EXTRACT | FULL TEXT  

RELATED LETTERS

Genomic Typing of Uveal Melanoma
Bertil Damato and Sarah E. Coupland
Arch Ophthalmol. 2009;127(1):113-114.
EXTRACT | FULL TEXT  

Genomic Typing of Uveal Melanoma—Reply
Jerry A. Shields, Carol L. Shields, Miguel Materin, Takami Sato, and Arupa Ganguly
Arch Ophthalmol. 2009;127(1):114.
EXTRACT | FULL TEXT  

Genomic Typing of Uveal Melanoma—Reply
Dennis M. Robertson
Arch Ophthalmol. 2009;127(1):114-115.
EXTRACT | FULL TEXT  

Genomic Typing of Uveal Melanoma—Reply
Tony Tsai and Joan M. O’Brien
Arch Ophthalmol. 2009;127(1):115.
EXTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2009 American Medical Association. All Rights Reserved.